T1	Participants 71 86	Graves' disease
T2	Participants 322 333	55 patients
T3	Participants 239 290	post-antithyroid drug treatment for Graves' disease
T4	Participants 1259 1309	patients with end-treatment TSAb greater than 350%
T5	Participants 1356 1393	patients with the highest TSAb levels
T6	Participants 1091 1155	End-treatment TSAb values, when low (less than 350%) or negative
T7	Participants 1462 1486	18 patients in remission
